Study of a new drug for healthy people and those with Stargardt disease
Part of Eyes & vision, Genetic & congenital clinical trials.
This study tests a new drug called CITY-RBP4 in healthy volunteers and in people with Stargardt disease (STGD1), a genetic condition that causes vision loss. The goal is to see if the drug is safe and how it affects the body, which may help guide future treatments for Stargardt disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 12 and 45 years old (healthy volunteers must be 18 to 45).
- You must have a confirmed diagnosis of Stargardt disease with a specific genetic change (for the Stargardt part of the study).
- You must have a certain level of vision in at least one eye (for the Stargardt part).
- You must be generally healthy, with no significant eye, heart, liver, kidney, or other medical conditions.
- You must not have had certain previous treatments, like gene therapy or stem cell therapy for your eyes.
- You must agree to use effective birth control or abstain from sex during the study and for a period after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with Stargardt disease (a genetic eye condition that causes vision loss) over time. It aims to learn more about how the disease progresses and does not test any treatment.
This trial tests a new gene therapy called VG801 for people with Stargardt disease, a genetic condition that causes vision loss. The treatment aims to improve or slow vision loss by delivering a working copy of the ABCA4 gene to the retina.
This trial tests an experimental medicine called ACDN-01 for people with Stargardt retinopathy caused by ABCA4 gene mutations. The goal is to see if it can slow or stop vision loss in an eye with already damaged central vision.
This prescreening study looks for people with a specific genetic eye condition called Stargardt disease to see if they might be able to join a future trial for a new treatment called ACDN-01.
This trial tests a new drug, ALK-001, to see if it can slow down vision loss from Stargardt disease. It is for people who have a confirmed genetic diagnosis and are between 8 and 45 years old.
This trial tests a single injection of a new medicine, RTx-021, into the eye for people with Stargardt disease. The goal is to see if it is safe and to find the right dose.
Hear when a new Stargardt Disease 1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.